抗體偶聯(lián)藥物、雙特異性抗體等新型抗體已成為近年來抗體工程領(lǐng)域的研究熱點，由于其具有特異性高、選擇性強和非細胞毒性等優(yōu)點，在腫瘤治療領(lǐng)域中具有廣闊的應(yīng)用前景。但該類藥物結(jié)構(gòu)和功能相對復雜，給安全性帶來特殊風險。在臨床前安全性評價中，需要根據(jù)其特點和可能介導的毒性作用機制，建立科學的評價方案。通過對新型抗體類藥物的類型、結(jié)構(gòu)特點、作用方式以及主要的毒性風險進行綜述，并結(jié)合已批準的新型抗體類藥物的非臨床安全性評價實例，探索新型抗體類藥物的臨床前安全性評價策略。

Antibody drug conjugates (ADCs) and Bispecific Antibodies are emerging as the promising class of new biopharmaceutical which have become a research focus in antibody engineering. Due to its specificity and less adverse effect,these new antibody drugs have a wide application future in cancer immunotherapy. From the nonclinical safety perspective, ADCs and Bispecific Antibodies present unique challenges to standard toxicology testing due to the complex components and mechanism of action. The impact of these biochemical differences on the safety must be considered when determining the types of nonclinical safety studies. The aim of this article is to review the unique characteristic, mode of action, determinants of toxicity, and preclinical studies of ADCs and Bispecific Antibodies to discuss how recent advances in our understanding of drug-mediated toxicity can be used to guide the types of preclinical safety studies.

十二五國家科技重大專項“生物大分子藥物特殊評價關(guān)鍵技術(shù)研究”（2015ZX09501007-004）；中國食品藥品檢定研究院中青年發(fā)展研究基金（2014C5）